Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Pemetrexed, High-dose Furmonertinib, and Bevacizumab for EGFR-mutant NSCLC with Leptomeningeal Metastases
NCT06537297Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Sep 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed, furmonertinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Primary endpoint: Leptomeningeal Metastases Overall Survival up to 24 months. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
pemetrexedfurmonertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06537297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06537297.